BPC-157 + TB-500 is a lyophilized research blend that combines two of the most widely studied repair-model peptides in one vial: BPC-157, a synthetic 15-residue peptide, and TB-500, thymosin β4. Each has its own preclinical literature. Unlike most blends, this pairing has also been tested together in at least one published animal study, which this overview covers along with where the evidence stops.
At a glance
- Type: Two-peptide lyophilized research blend
- Components: BPC-157 and TB-500 (thymosin β4)
- Amounts: The amount of each component is listed on the batch COA
- Research basis: Separate preclinical literatures for each peptide, plus one exploratory rat study of the two combined
- Regulatory status: Neither is an FDA-approved drug; both are on the WADA Prohibited List
Why laboratories pair these two
BPC-157 and thymosin β4 come from unrelated sources, but their research overlaps heavily: both have been studied in tendon, wound and vascular models, and both are discussed in work on cell migration. That overlap is why they are so often compared, and why a combined vial, made as a single lot with a single certificate of analysis, is useful to labs running side-by-side models.
The two components
BPC-157
BPC-157 is a synthetic pentadecapeptide developed and characterized by Predrag Sikiric’s group at the University of Zagreb. Rat and cell studies report effects on tendon fibroblast outgrowth, survival and migration (Chang et al., 2011), and a body of work examines its interaction with blood vessels (Seiwerth et al., 2014). Read the full BPC-157 research overview.
TB-500 (thymosin β4)
Thymosin β4 is a 43-residue protein best known for binding and sequestering actin monomers (Safer et al., 1991). In culture it promoted directional migration of endothelial cells (Malinda et al., 1997), and it has since been studied in cardiac, dermal and tendon injury models. Read the full TB-500 research overview.
Research on the combination
A 2026 rat Achilles tendon study compared TB-500, BPC-157 and the two given together, using histopathology and biomechanical load testing (Biçer et al., 2026). The authors described their results as exploratory. One rodent study is a starting point, not an established finding, and it does not say how the two peptides interact in a single preparation.
What the evidence does not show
- The research on each component comes from cell culture and animal models. It does not establish any effect in humans.
- Findings for a single peptide cannot be assumed to hold when it is combined with others; the components could interact in ways no study has measured.
- The only combination study is a single exploratory rat study; it has not been replicated.
- Several of the literatures come from a small number of research groups, and some findings have not been independently replicated.
Regulatory status
Neither component is approved by the FDA as a drug. BPC-157 has been on the WADA Prohibited List under S0 since 2022, and thymosin β4 and its derivatives fall under WADA S2. The BPC-157 + TB-500 blend sold by Rogue Compounds is a research reagent for laboratory use only. It is not for human consumption.
Handling and storage in the lab
Lyophilized BPC-157 + TB-500 should be kept sealed and refrigerated at 2–8°C (36–46°F), protected from light.
Sourcing and documentation
Rogue Compounds has BPC-157 + TB-500 made in small batches. Every vial carries a batch number and a QR code that opens the independent U.S. testing lab’s own report for that batch, and the same batch COA, including the amount of each component, is on the product page and in the COA Library.
View BPC-157 + TB-500 on Rogue Compounds
References
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. PMID 21030672
- Seiwerth S, et al. BPC 157 and blood vessels. Curr Pharm Des. 2014;20(7):1121-1125. PMID 23782145
- Safer D, et al. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029-4032. PMID 1999398
- Malinda KM, et al. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 1997;11(6):474-481. PMID 9194528
- Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. PMID 42542926